Indeed, reduced levels of MIAT in PC9 lung cancer cells were recently found to be associated with a decrease in Bcl-2 and an increase in Bax expression levels [28], providing further evidence that associates reduced MIAT levels with an enhanced responses to a diverse range of cell death stimuli and raising the possibility that increased MIAT levels might contribute to the development of drug resistance in metastatic disease. The gene discussed is BCL2; the disease is metastatic neoplasm.